Ceftolozane/tazobactam in action: Prescribing patterns, effectiveness, and healthcare utilisation across seven...

Infections by antimicrobial-resistant, Gram-negative bacteria present significant global challenge, resulting in difficult treatment scenarios and poor clinical outcomes. Although ceftolozane/tazobactam (C/T) has been approved for the treatment of hospital-acquired HABP/VABP, cUTI, and cIAI, data on real-world use remains limited. This study presents real-world use of C/T across various countries.

The Study of Prescribing patterns and Effectiveness of Ceftolozane/Tazobactam: Real-world Analysis (SPECTRA) was a retrospective, observational study involving 617 adult inpatients across seven countries who were treated with C/T for at least 48 hours between 2016 and 2020. The primary objective was to describe real-world utilisation of C/T, focusing on sociodemographic and clinical characteristics, treatment patterns, clinical outcomes, and resource utilisation.

617 patients from seven countries were included. Prevalence of at least one comorbidity ranged from 55.9% (Mexico) to 91.7% (Austria), with mean number of comorbidities from 1.0 (Mexico) to 2.7 (UK). Culture results from 72.7% patients identified MDR Pseudomonas aeruginosa, ranging from 55.9% (Italy) to 80.6% (Spain). Median hospital length of stay ranged from 23 (Mexico) to 53.5 (Austria) days. Clinical success rate for treating the index infection with C/T was 64.8%, with 51.1% of cases treated within the ICU.

This multi-national, retrospective, observational study demonstrates the real-world use and healthcare resource utilisation (HCRU) of C/T in patients with Gram-negative infections across seven countries. These findings provide valuable insights into prescribing patterns and resource implications of C/T treatment, underscoring the importance of real-world data to inform clinical practice and optimise antimicrobial therapy in diverse healthcare settings.